Dr Reddy’s Laboratories Ltd will appeal the decision made by the US District Court for the District of New Jersey in a preliminary injunction hearing with respect to further sales and commercialisation of Dr Reddy’s Buprenorphine and Naloxone Sublingual Film within the US.
“The company disagrees with the court’s decision, and will vigorously appeal it,’’ it said in a release issued here on Saturday. Dr Reddy’s had announced the receipt of the approval on June 15, 2018 by one of its wholly-owned subsidiaries, from the US Food and Drug Administration (USFDA) for its Buprenorphine and Naloxone Sublingual film.
It’s an equivalent generic version of Suboxone (buprenorphine and naloxone) sublingual film in the US market.